NICE recommends Celgene's Ozanimod to treat ulcerative colit...

The new treatment with ozanimod (also known as zeposia) will benefit over 12,000 adults who suffer from moderate to severe active ulcerative colitis (UC).

Data sets up ulcerative colitis expansion for BMS’ MS drug Z...

Bristol-Myers Squibb’s Zeposia (ozanimod) is already tipped for blockbuster sales in its first indication – multiple sclerosis – and new data in ulcerative colitis suggests they could climb

BMS gets FDA nod for ozanimod, but launch will be delayed

Celgene gets MS blockbuster-in-waiting ozanimod back on trac...

Regulators in the US and EU have formally started their review of Celgene’s oral drug ozanimod for multiple sclerosis, setting up verdicts next year.

Ozanimod launch delayed by failures in FDA application

The launch of Celgene’s multiple sclerosis drug, ozanimod, will be delayed after the company failed to submit key information in its application to the Food and Drug Administration (FDA).